Biomimetic Therapeutics Inc

Biomimetic Therapeutics — Technical Presentation (November 2006)

14 slides from Biomimetic Therapeutics's technical presentation, Nov 6, 2006

  1. Slide 1: rhPDGF-BB: A Novel Tissue Engineering System for the Future?

    rhPDGF-BB A Novel Tissue Engineering System for the Future? Dr. Tim Daniels MD FRCSC Associate Professor St. Michael's Hospital University of Toronto

  2. Slide 2: Delayed Union / Nonunion

    Delayed Union / Nonunion "In this study, the nonunion rate was 41%, the worst in the literature." Majority of the patients were post-traumatic. Highest incidence in patients with plafond/talus fractures A review of ankle arthrodesis: predisposing factors to nonunion. Frey C et al Foot Ankle Int. 199

  3. Slide 3: Delayed Union / Nonunion: Subtalar Arthrodesis

    Delayed Union / Nonunion 184 consecutive isolated subtalar arthrodesis Overall nonunion rate = 16% Nonunion rate: Nonsmokers - 8% Smokers - 27% Nonunion rate in: Primary fusion - 14% Revision fusion - 29% Isolated Subtalar Arthrodesis Easley ME, Trnka HJ, Schon LC and Myerson MS J Bone Joint Surg Am

  4. Slide 4: Delayed Union / Nonunion: Ankle and Hindfoot Fusions

    Delayed Union / Nonunion 63 complex ankle or hindfoot fusions Grafton putty and Orthoblast used - demineralized bone graft Overall nonunion rate - 11% Use of demineralized bone matrix in ankle/hindfoot fusion. Thoradson DB and Kuehn S. Foot Ankle Int. 2003 Jul;24(7):557-60.

  5. Slide 5: The Pilot Study

    The Pilot Study Purpose Safety and clinical utility (i.e. performance) in representative bone regeneration model "First-in-man" clinical experience in foot and ankle orthopedic application Study Design Investigators: SMH, Toronto Western, British Columbia F/A Clinic Open-label pilot trial Independen

  6. Slide 6: Study Flowchart

    Study Flowchart Procedure Screening Surgery Post-Treatment Follow-up Evaluations Post-Treatment Follow-up Evaluations Post-Treatment Follow-up Evaluations Post-Treatment Follow-up Evaluations Post-Treatment Follow-up Evaluations Post-Treatment Follow-up Evaluations Post-Treatment Follow-up Evaluatio

  7. Slide 7: Inclusion / Exclusion Criteria

    Inclusion / Exclusion Criteria Key Inclusion Criteria REB approved informed consent Bone defect in foot/ankle fusion requiring bone graft No more than 4 screws ^ 16 years of age Key Exclusion Criteria Previous surgery with infection at fusion site Plate fixation or >9cc of bone graft (no more than 3

  8. Slide 8: Surgical Procedure

    Surgical Procedure Surgical Technique Standard anesthesia protocol Entire joint exposed and denuded to subchondral bone Cortex is perforated to augment fusion Fusion hardware: screws (^ 4), supplemental pins; no plates Fixation must be rigid prior to wound closure Document start and stop times (firs

  9. Slide 9: Patient Demographics

    Number of Subjects 32 Mean Age 51 Gender Male - 13 (41%) Gender Female - 19 (59%) Mean Body Mass Index 29.9 (22 - 50) Smoking History Prior Smoking History - 13 (41%) Current Smoker - 6 (19%) Description of Injury / Deformity Primary Arthritis - 9 (29%) Rheumatoid Arthritis - 2 (6%) Post-Traumatic I

  10. Slide 10: Patient Risk Factors

    Obese (^ 30 kg/m2) 14 (44%) Previous Surgery (revision) 13 (41%) History of Diabetes (Type I or II) 4 (13%) Smoking History within Last 5 yrs. 8 (25%) Subjects with multiple risk factors 14 (44%) Patient Risk Factors At-risk patient population included in pilot study

  11. Slide 11: Adverse Events

    Adverse Events Event GEM OS1 Subjects With at Least One Adverse Event 21 Total Adverse Events 36 Surgical Complications 18 Serious Adverse Events 2 Infections (soft tissue) 3 Abnormal / Heterotopic Bone Formation 0 Adverse Events Attributable to Device 0 No device related AEs / SAEs reported to date

  12. Slide 12: Clinical Outcomes

    Timepoint Subjects Achieving FWB Status (%) Baseline N/A Week 6 2 / 32 (6%) Week 12 20 / 30 (67%) Week 16 17 / 19 (90%) Week 24 9 / 9 (100%) Clinical Outcomes All 24 week f/u patients have achieved FWB status

  13. Slide 13: Radiographic Outcomes

    Timepoint Moderate or Complete (> 50%) Week 6 8 / 27 (30%) Week 12 18 / 27 (67%) Radiographic Outcomes Independent Radiologist Assessment: Osseous Bridging (CT Scans) 85% of subjects undergoing fusions in this current study had some degree of osseous bridging noted at 12 weeks on CT scan Recent CT o

  14. Slide 14: Conclusions

    Conclusions Summary of Top Line Results for rhPDGF-BB / GEM OS1 To date this is a safe alternative to autogenous bone graft: Results comparable and suggest to be better than ABG without associated harvest morbidity No device related AEs/SAEs Additional RCTs are warranted to prove efficacy Expanded s

BioMimetic Therapeutics — Technical Presentation (November 2006) on 6ix